Ventilator-associated pneumonia in pediatric cardiac intensive care

Background: This study aimed to evaluate the incidence of ventilator-associated pneumonia (VAP) and identify the risk factors contributing to its development in pediatric cardiac intensive care units. Methods: This retrospective study analyzed cases of patients <18 years old hospitalized in a pediatric cardiac intensive care unit between 01 January 2021, and 01 January 2024. Data patients diagnosed with VAP were matched (age and surgical procedure) with those of two control patients based. Results: During the study period, 1650 cardiac operations were performed. Among these, 520 cases requiring mechanical ventilation for more than 48 hours were included in the analysis. A total of 40 cases of VAP were identified and matched with 80 control cases. The incidence density of VAP was found to be 17.2 per 1000 ventilator days, and the median age of patients with VAP was two months. The isolated pathogens included Klebsiella pneumoniae (n = 14, 35%), Stenotrophomonas maltophilia (n = 7, 17.5%), Pseudomonas aeruginosa (n = 6, 15%), Acinetobacter baumannii (n = 6, 15%), Staphylococcus aureus (n = 4, 10%) and Enterobacter species (n = 3, 7.5%). The mortality rate in patients with VAP was 20% (8/40). Data analysis showed that independent risk factors for VAP included a RACHS-1 (Risk Adjustment for Congenital Heart Surgery) score of ≥4, the use of extracorporeal membrane oxygenation (ECMO), central venous catheterization lasting ≥14 days, mechanical ventilation dependency for ≥10 days, requirement for total parenteral nutrition, and delayed sternal closure of ≥2 days. Conclusions: VAP represents a significant cause of morbidity and mortality in pediatric cardiac intensive care units after congenital heart surgery. Gram-negative bacteria were identified as the predominant pathogens in this population.

Congenital heart disease; Ventilator-associated pneumonia; Intensive care unit

[1] van der Linde D, Konings EE, Slager MA, Witsenburg M, Helbing WA, Takkenberg JJ, et al. Birth prevalence of congenital heart disease worldwide: a systematic review and meta-analysis. Journal of the American College of Cardiology. 2011; 58: 2241–2247.

[2] Jacobs JP, Jacobs ML, Mavroudis C, Backer CL, Lacour-Gayet FG, Tchervenkov CI, et al. Nomenclature and databases for the surgical treatment of congenital cardiac disease: an updated primer and an analysis of opportunities for improvement. Cardiology in the Young. 2008; 18: 38–62.

[3] Elward AM, Warren DK, Fraser VJ. Ventilator-associated pneumonia in pediatric intensive care unit patients: risk factors and outcomes. Pediatrics. 2002; 109: 758–764.

[4] Shaath GA, Jijeh A, Faruqui F, Bullard L, Mehmood A, Kabbani MS. Ventilator-associated pneumonia in children after cardiac surgery. Pediatric Cardiology. 2014; 35: 627–631.

[5] Tang CW, Liu PY, Huang YF, Pan JY, Lee SS, Hsieh KS, et al. Ventilator-associated pneumonia after pediatric cardiac surgery in southern Taiwan. Journal of Microbiology, Immunology and Infection. 2009; 42: 413–419.

[6] Horan TC, Andrus M, Dudeck MA. CDC/NHSN surveillance definition of health care-associated infection and criteria for specific types of infections in the acute care setting. American Journal of Infection Control. 2008; 36: 309–332.

[7] Özalp Ş, Dilek Özcanoğlu H, Öztürk E, Sağlam S, Kahraman İA, Tan ZB, et al. Assessment of the factors that affect fast-track or early extubation following pediatric cardiac surgery. Turkish Journal of Thoracic and Cardiovascular Surgery. 2023; 31: 1–7.

[8] Galal YS, Youssef MR, Ibrahiem SK. Ventilator-associated pneumonia: incidence, risk factors and outcome in paediatric intensive care units at Cairo university hospital. Journal of Clinical and Diagnostic Research. 2016; 10: SC06–SC11.

[9] Tablan OC, Anderson LJ, Besser R, Bridges C, Hajjeh R; CDC; Healthcare Infection Control Practices Advisory Committee. Guidelines for preventing health-care—associated pneumonia, 2003: recommendations of CDC and the Healthcare Infection Control Practices Advisory Committee. MMWR Recommendations and Reports. 2004; 53: 1–36.

[10] Mohamed HT, Farhan Alenezi WA Sr, Alanzi MAA, Saleh Alsuqub FI, Salem Alhazmi SA, Mohammed Alhazmi OM. Prevalence of ventilator-associated pneumonia in children admitted to pediatric ‎intensive care units in the middle east: a systematic review. Cureus. 2023; 15: e51230.

[11] Roeleveld PP, Guijt D, Kuijper EJ, Hazekamp MG, de Wilde RB, de Jonge E. Ventilator-associated pneumonia in children after cardiac surgery in The Netherlands. Intensive Care Medicine. 2011; 37: 1656–1663.

[12] Tan L, Sun X, Zhu X, Zhang Z, Li J, Shu Q. Epidemiology of nosocomial pneumonia in infants after cardiac surgery. Chest. 2004; 125: 410–417.

[13] Sun YL, Fu YQ, Ma HT, Liu CJ, Xu F. Pathogens and risk factors for ventilator-associated pneumonia in children with congenial heart disease after surgery. Chinese Journal of Contemporary Pediatrics. 2015; 17: 1204–1209. (In Chinese)

[14] Singh D, Sahu MK, Singh SP, Singh U, Shiv C, Shivam P. Outcome of ventilator-associated pneumonia in children post cardiac surgery: a prospective observational study. Journal of Cardiac Critical Care TSS. 2022; 6: 033–039.

[15] Banar M, Sattari-Maraji A, Bayatinejad G, Ebrahimi E, Jabalameli L, Beigverdi R, et al. Global prevalence and antibiotic resistance in clinical isolates of Stenotrophomonas maltophilia: a systematic review and meta-analysis. Frontiers in Medicine. 2023; 10: 1163439.

[16] Mojica MF, Humphries R, Lipuma JJ, Mathers AJ, Rao GG, Shelburne SA, et al. Clinical challenges treating Stenotrophomonas maltophilia infections: an update. JAC-Antimicrobial Resistance. 2022; 4: dlac040.

[17] Carbonell N, Oltra MR, Clari MÁ. Stenotrophomonas maltophilia: the landscape in critically Ill patients and optimising management approaches. Antibiotics. 2024; 13: 577.

[18] Antalová N, Klučka J, Říhová M, Poláčková S, Pokorná A, Štourač P. Ventilator-associated pneumonia prevention in pediatric patients: narrative review. Children. 2022; 9: 1540.